<?xml version="1.0" ?>
<tei type="journal-article">
	<teiHeader>
		<fileDesc xml:id="55114447"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<reference>HUMAN GENE THERAPY 15:1131–1154 (November 2004)<lb/></reference>

	<note type="copyright">© Mary Ann Liebert, Inc.<lb/></note>

	<docTitle>
	<titlePart>Clinical Protocol<lb/> Administration of a Replication-Deficient Adeno-Associated<lb/> Virus Gene Transfer Vector Expressing the Human CLN2<lb/> cDNA to the Brain of Children with Late Infantile Neuronal<lb/> Ceroid Lipofuscinosis<lb/></titlePart>
	</docTitle>

	<idno>FDA-IND #11481<lb/> NIH (RAC) #0312-619<lb/></idno>

	<note type="other">PRINCIPAL INVESTIGATOR: </note>
		
	<byline>
	<docAuthor>Ronald G. Crystal 1<lb/> </docAuthor>
	</byline>

	<byline>
	<affiliation>SITE:<lb/> New York Presbyterian Hospital-Cornell Medical Center<lb/> </affiliation>
	</byline>
	
	<note type="other">COINVESTIGATORS:<lb/></note>

	<byline>
	<docAuthor>Dolan Sondhi, Ph.D., 1 Neil R. Hackett, Ph.D., 2 Stephen M. Kaminsky,<lb/> Ph.D., 2 Stefan Worgall, M.D., 3 Philip Stieg, M.D., Ph.D., 4 Mark Souwei-<lb/>dane, M.D., 4 Syed Hosain, M.D., 3 Linda Heier, M.D., 5 Douglas Ballon,<lb/> Ph.D., 5 Miles Dinner, M.D., 6 Krystyna Wisniewski, M.D., Ph.D., 7 Michael<lb/> Kaplitt, M.D., Ph.D., 4 Bruce M. Greenwald, M.D., 3 Joy D. Howell, M.D., 3<lb/> Kristin Strybing, N.P., 4 Jonathan Dyke, Ph.D., 5 and Henning Voss, Ph.D. 5<lb/> </docAuthor>
	</byline>

	<byline>
	<affiliation>AFFILIATIONS:<lb/>1 Department of Genetic Medicine, Weill Medical College of Cornell Uni-<lb/>versity,</affiliation>
	</byline>

	<address>New York, NY 10021 (WMC),</address>

	<byline>
	<affiliation>2 Department of Medicine,</affiliation>
	</byline>

	<address>WMC,<lb/></address>

	<byline>
	<affiliation>3 Department of Pediatrics,</affiliation>
	</byline>

	<address>WMC,</address>

	<byline>
	<affiliation>4 Department of Neurological Surgery,<lb/></affiliation>
	</byline>
 
	<address>WMC,</address>

	<byline>
	<affiliation>5 Department of Radiology, WMC, 6 Department of Anesthesiology,<lb/></affiliation>
	</byline>

	<address>WMC,</address>

	<byline>
	<affiliation>7 Institute for Basic Research in Developmental Disabilities,</affiliation>
	</byline>

	<address>Staten<lb/> Island, NY 10314.<lb/></address>

	<note type="other">TABLE OF CONTENTS<lb/></note>

	<note type="other">Overview of Late Infantile Neuronal Ceroid Lipofuscinosis<lb/> Rationale for In Vivo Gene Therapy for the CNS Manifestations of LINCL<lb/> Adeno-associated Serotype 2 Gene Transfer Vectors<lb/> Overview of the Proposed Study<lb/> Details of the Experimental Design<lb/> End-Point Variables<lb/> Primary End Point<lb/> Secondary End Point<lb/> Review and Monitoring<lb/> Statistical Considerations<lb/> Timeline Inclusion/Exclusion Criteria<lb/> Inclusion Criteria<lb/> Exclusion Criteria<lb/> Risks of the Study<lb/> Delivery of the Vector and Surgical Procedures<lb/> AAV2 CU hCLN2 Vector<lb/> Tests and Procedures Designed to Evaluate Effectiveness and Safety<lb/> Precautions to Minimize Risks<lb/> Management of Intercurrent Illness<lb/> Management of Adverse Events
	<lb/></note>
	
	<note type="page">1131</note>

		</front>
	</text>
</tei>
